April 21 marks AML World Awareness Day — a global effort to boost recognition of acute myeloid leukemia (AML) and raise funds for research…
Blood cancer
The first patient has been dosed in a Phase 1 clinical trial evaluating the safety and early efficacy of STX-0712 in people with resistant or…
Exportin-1, a therapeutic target for nuclear export inhibitors — a class of drugs used to treat blood cancers including multiple myeloma and leukemia…
The first patient has been dosed in a Phase 3 clinical trial testing ICP-248 (mesutoclax) in combination with orelabrutinib in adults with chronic lymphocytic leukemia…
Orca-T, Orca Bio‘s investigational allogeneic stem cell transplant for treating blood cell cancers, more than doubled the rate of survival free from moderate…
Chromoanagenesis — an abnormal rearrangement of DNA within the chromosomes of certain cells, including blood cells — links with limited treatment response and poorer outcomes…
China has granted breakthrough therapy designation to olverembatinib to be used with low-intensity chemotherapy as a first-line treatment for newly diagnosed people with Philadelphia chromosome-positive…
A European Medicines Agency (EMA) committee recommended that Jaypirca (pirtobrutinib) be approved to treat some adult patients with chronic lymphocytic leukemia (CLL), a type of…
Aptose Biosciences will be testing a higher dose of tuspetinib as part of a triple-combination regimen that’s being explored in a clinical trial…
A triple-combination therapy using tuspetinib, Aptose Biosciences‘ experimental oral therapy, is showing potential in treating adults with newly diagnosed acute myeloid leukemia (AML),…
